department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Vanda Pharmaceuticals Inc. ($VNDA) · pharmadog

PUBLIC COMPANY

$VNDAVanda Pharmaceuticals Inc.

Washington, DC, USupdated just now

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

9

marketed

6

phase 3

0

catalysts ytd

2

approvals ytd

1

recalls ytd

0

Pipeline(9)

pipeline depth9 products

2Phase 26Marketed1pre_registration

Circadian Rhythm Sleep Disorders

Bipolar I Disorder

Marketed

milsaperidone

Major Depressive Disorder

Ulcerative Colitis

Sphingosine 1-phosphate receptor 1

Circadian Rhythm Sleep Disorders

Motion Sickness

Charcot-Marie-Tooth Disease Type II

Onychomycosis (Tinea Unguium)

pre_registration

Generalized Pustular Psoriasis (GPP)

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

Vanda Pharmaceuticals Inc. earnings

Vanda Pharmaceuticals Inc.

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Vanda Pharmaceuticals Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$VNDA

SEC CIK

0001347178

country

US

source

sec_tickers

top tags

Immunology2 Schizophrenia2 IBD (Crohn's + UC)1 Infectious Disease1 Major Depression1

mentioned in

0news items

entity-linker matched

Active trials

phase3A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Userecruitingn=280
phase3Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sicknessactive not recruitingn=705
phase3Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorderrecruitingn=500
phase3Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPterminatedn=42
phase3Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPcompletedn=45
phase1Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignanciesrecruitingn=42
phase2Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertensionrecruitingn=240
phase3Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorderrecruitingn=500

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$VNDA6.2300+0.32%

Data sources

SEC EDGAR · openFDA

last refreshed just now

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$VNDA6.2300+0.32%

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 2, 26SELLPolymeropoulos Mihael Hristos· President and CEO156,235 sh @ $8.17−$1.28M↗
Mar 2, 26SELLMoran Kevin Patrick· SVP, CFO & Treasurer42,442 sh @ $8.27−$351K↗
Mar 2, 26SELLWilliams Timothy· SVP & General Counsel42,434 sh @ $8.27−$351K↗
Mar 2, 26SELLBirznieks Gunther· SVP, Business Development42,431 sh @ $8.27−$351K↗
Mar 2, 26SELLWijkstrom Joakim· SVP, Chief Marketing Officer30,800 sh @ $8.27−$255K↗
Feb 23, 26SELLHonore Tage· director30,000 sh @ $8.03−$241K↗

routine RSU / option mechanics (6)

Apr 22, 26grantDuncan Charles Cliff · director57,101 sh
Feb 18, 26grantWijkstrom Joakim · SVP, Chief Marketing Officer125,000 sh
Feb 18, 26grantBirznieks Gunther · SVP, Business Development125,000 sh
Feb 18, 26grantWilliams Timothy · SVP & General Counsel125,000 sh
Feb 18, 26grantMoran Kevin Patrick · SVP, CFO & Treasurer125,000 sh

Feb 18, 26

grant

Polymeropoulos Mihael Hristos · President and CEO

525,000 sh